# Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

> **NCT07346079** · PHASE4 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Gout Arthritis
- Gout Flare
- Gout

## Interventions

- **DRUG:** Purified Cortophin Gel, 40 U
- **DRUG:** Purified Cortophin Gel 80 U

## Key facts

- **NCT ID:** NCT07346079
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07346079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07346079, "Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT07346079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*